REFERENCES
1. Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther. 2019;2019:8295054.
2. Leong DP, Joseph PG, McKee M, et al. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circ Res. 2017;121:695-710.
3. Townsend N, Kazakiewicz D, Lucy Wright F, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022;19:133-43.
4. Soppert J, Lehrke M, Marx N, Jankowski J, Noels H. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Delivery Rev. 2020;159:4-33.
5. Wang W, Hu M, Liu H, et al. Global burden of disease study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell Metab. 2021;33:1943-56.e2.
6. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138-53.
7. Fowkes R, Byrne M, Sinclair H, Tang E, Kunadian V. Coronary artery disease in patients with dementia. Coron Artery Dis. 2016;27:511-20.
8. Stakos DA, Stamatelopoulos K, Bampatsias D, et al. The Alzheimer's disease amyloid-beta hypothesis in cardiovascular aging and disease: JACC focus seminar. J Am Coll Cardiol. 2020;75:952-67.
9. Huang X, Wang Z, Lei F, et al. Association of urban environments with Atherosclerotic cardiovascular disease: A prospective cohort study in the UK Biobank. Environ Int. 2024;193:109110.
10. Sun T, Yang J, Lei F, et al. Artificial sweeteners and risk of incident cardiovascular disease and mortality: evidence from UK Biobank. Cardiovasc Diabetol. 2024;23:233.
11. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691-705.
12. Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2025;10:e203-27.
13. 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23:344-81.
14. Ding D, Zhou D, Sander JW, Wang W, Li S, Hong Z. Epilepsy in China: major progress in the past two decades. Lancet Neurol. 2021;20:316-26.
15. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88:296-303.
16. De Luca R, Arrè V, Nardone S, et al. Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling. Gut. 2025;75:161-75.
17. Symonds JD, Elliott KS, Shetty J, et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain. 2021;144:2879-91.
18. Singh G, Sander JW. The global burden of epilepsy report: Implications for low- and middle-income countries. Epilepsy Behav. 2020;105:106949.
19. Stefanidou M, Himali JJ, Devinsky O, et al. Vascular risk factors as predictors of epilepsy in older age: The Framingham Heart Study. Epilepsia. 2022;63:237-43.
20. Devinsky O, Spruill T, Thurman D, Friedman D. Recognizing and preventing epilepsy-related mortality: a call for action. Neurology. 2016;86:779-86.
21. Ellis CA, Petrovski S, Berkovic SF. Epilepsy genetics: clinical impacts and biological insights. Lancet Neurol. 2020;19:93-100.
22. Thurman DJ, Logroscino G, Beghi E, et al. The burden of premature mortality of epilepsy in high-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia. 2017;58:17-26.
23. Mayer J, Fawzy AM, Bisson A, et al. Epilepsy and the risk of adverse cardiovascular events: A nationwide cohort study. Eur J Neurol. 2024;31:e16116.
24. Fialho GL. Epilepsy and the heart: can 'brain arrhythmia' lead to cardiac arrhythmias? Back to the basics. Eur Heart J. 2024;45:853-4.
26. Husein N, Josephson CB, Keezer MR. Understanding cardiovascular disease in older adults with epilepsy. Epilepsia. 2021;62:2060-71.
27. Nyberg J, Aberg MA, Torén K, Nilsson M, Ben-Menachem E, Kuhn HG. Cardiovascular fitness and later risk of epilepsy: a Swedish population-based cohort study. Neurology. 2013;81:1051-7.
28. Neri S, Gasparini S, Pascarella A, et al. Epilepsy in cerebrovascular diseases: a narrative review. Curr Neuropharmacol. 2023;21:1634-45.
29. Hesdorffer DC, Tomson T, Benn E, et al. Combined analysis of risk factors for SUDEP. Epilepsia. 2011;52:1150-9.
30. Xu K, Gao X, Xia G, et al. Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn. Gut. 2021;70:1486-94.
31. Ioannou P, Foster DL, Sander JW, et al. The burden of epilepsy and unmet need in people with focal seizures. Brain Behav. 2022;12:e2589.
32. Terrone G, Salamone A, Vezzani A. Inflammation and epilepsy: preclinical findings and potential clinical translation. Curr Pharm Des. 2017;23:5569-76.
33. Simats A, Sager HB, Liesz A. Heart-brain axis in health and disease: role of innate and adaptive immunity. Cardiovasc Res. 2025;120:2325-35.
34. Wannamaker BB, Wilson DA, Malek AM, Selassie AW. Stroke after adult-onset epilepsy: a population-based retrospective cohort study. Epilepsy Behav. 2015;43:93-9.
35. Zack M, Luncheon C. Adults with an epilepsy history, notably those 45-64 years old or at the lowest income levels, more often report heart disease than adults without an epilepsy history. Epilepsy Behav. 2018;86:208-10.
36. Terman SW, Aubert CE, Hill CE, Skvarce J, Burke JF, Mintzer S. Cardiovascular disease risk, awareness, and treatment in people with epilepsy. Epilepsy Behav. 2021;117:107878.
37. Shah RA, Chahal CAA, Ranjha S, et al. Cardiovascular disease burden, mortality, and sudden death risk in epilepsy: a UK biobank study. Can J Cardiol. 2024;40:688-95.
38. Annegers JF, Hauser WA, Shirts SB. Heart disease mortality and morbidity in patients with epilepsy. Epilepsia. 1984;25:699-704.
39. Bucci T, Mbizvo GK, Rivera-Caravaca JM, et al. Epilepsy-heart syndrome: incidence and clinical outcomes of cardiac complications in patients with epilepsy. Curr Probl Cardiol. 2023;48:101868.
40. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.
41. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203-9.
42. Thompson DJ, Wells D, Selzam S, et al. A systematic evaluation of the performance and properties of the UK biobank polygenic risk score (PRS) release. PLoS ONE. 2024;19:e0307270.
43. International League Against Epilepsy Consortium on Complex Epilepsies. Electronic address: [email protected]. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol. 2014;13:893-903.
44. International League Against Epilepsy Consortium on Complex Epilepsies. GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture. Nat Genet. 2023;55:1471-82.
45. Heyne HO, Pajuste FD, Wanner J, et al. Polygenic risk scores as a marker for epilepsy risk across lifetime and after unspecified seizure events. Nat Commun. 2024;15:6277.
46. Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. Nat Rev Cardiol. 2022;19:291-301.
48. Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Web site and R package for computing E-values. Epidemiology. 2018;29:e45-7.
49. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268-74.
50. Costagliola G, Orsini A, Coll M, Brugada R, Parisi P, Striano P. The brain-heart interaction in epilepsy: implications for diagnosis, therapy, and SUDEP prevention. Ann Clin Transl Neurol. 2021;8:1557-68.
53. Rana A, Musto AE. The role of inflammation in the development of epilepsy. J Neuroinflammation. 2018;15:144.
54. International League Against Epilepsy Consortium on Complex Epilepsies. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun. 2018;9:5269.
55. Sivathamboo S, Liu Z, Sutherland F, et al. Serious cardiac arrhythmias detected by subcutaneous long-term cardiac monitors in patients with drug-resistant epilepsy. Neurology. 2022;98:e1923-32.
56. Hall SA, Lesniewski LA. Targeting vascular senescence in cardiovascular disease with aging. J Cardiovasc Aging. 2024;4:16.
57. Muthu S, Tran Z, Thilagavathi J, et al. Aging triggers mitochondrial, endoplasmic reticulum, and metabolic stress responses in the heart. J Cardiovasc Aging. 2025;5:4.
58. Sun Q, Karwi QG, Wong N, Lopaschuk GD. Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond. Cardiovasc Res. 2024;120:1996-2016.
59. Dichgans M, Malik R, König IR, et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke. 2014;45:24-36.
60. Verrier RL, Pang TD, Nearing BD, Schachter SC. Epileptic heart: a clinical syndromic approach. Epilepsia. 2021;62:1780-9.
62. Wang J, Huang P, Yu Q, et al. Epilepsy and long-term risk of arrhythmias. Eur Heart J. 2023;44:3374-82.
63. Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012;53:120-8.
64. Beghi E, Bizzi A, Codegoni AM, Trevisan D, Torri W. Valproate, carnitine metabolism, and biochemical indicators of liver function. Collaborative Group for the Study of Epilepsy. Epilepsia. 1990;31:346-52.
65. Li J, Shlobin NA, Thijs RD, et al. Antiseizure medications and cardiovascular events in older people with epilepsy in the canadian longitudinal study on aging. JAMA Neurol. 2024;81:1178-86.
66. MacLeod C, Hadoke PWF, Nixon M. Glucocorticoids: fuelling the fire of atherosclerosis or therapeutic extinguishers? Int J Mol Sci. 2021:22.
67. Xu Y, Fan Q. Relationship between chronic hypoxia and seizure susceptibility. CNS Neurosci Ther. 2022;28:1689-705.
68. Grigg-Damberger M, Foldvary-Schaefer N. Hypoxia not AHI in adults with sleep apnea midlife markedly increases risk of late-onset epilepsy-Carosella CM et al Sleep apnea, hypoxia, and late-onset epilepsy: the Atherosclerosis Risk in Communities study SLEEP-2023-0175.R1. Sleep. 2024;47:zsad252.
